Through access to AstraZeneca’s extensive compound library, MMV will seek to identify promising compounds with the potential to treat malaria.
AstraZeneca and Medicines for Malaria Venture (MMV) today announced a collaborative agreement designed to identify novel candidate drugs for the treatment of malaria. The agreement will initially allow MMV access to AstraZeneca’s extensive compound library. MMV will seek to identify promising compounds with the potential to treat malaria, including drug resistant strains of the disease. AstraZeneca CEO David Brennan announced the collaboration at the Fortune/TIME/CNN Global Forum in Cape Town, South Africa.
Tim Wells, MMV’s Chief Scientific Officer said: “AstraZeneca has had a long standing interest in neglected disease, and we are delighted to be able to collaborate with the centre in Bangalore on this exciting project in malaria. The screening of their library will give us some new unique starting points. However, the additional advantage is the Indian perspective: India has millions of cases of malaria per year, and in addition has a balance between Plasmodium falciparum and Plasmodium vivax. Understanding and eliminating Indian malaria is one of the keys to eliminating malaria worldwide.”